Prognostic significance of pathological complete response in non-small cell lung cancer following neoadjuvant treatment.
Neoadjuvant treatment
non-small cell lung cancer
pathological complete response
Journal
Turk gogus kalp damar cerrahisi dergisi
ISSN: 1301-5680
Titre abrégé: Turk Gogus Kalp Damar Cerrahisi Derg
Pays: Turkey
ID NLM: 100887967
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
09
08
2019
accepted:
08
11
2019
entrez:
17
3
2020
pubmed:
17
3
2020
medline:
17
3
2020
Statut:
epublish
Résumé
This study aims to investigate the factors associated with pathological complete response following neoadjuvant treatment and to examine the prognostic value of pathological complete response in patients with non-small cell lung cancer undergoing surgical resection. Between February 2009 and January 2016, a total of 112 patients (96 males, 16 females; mean age 60±8 years; range, 37 to 85 years) with the diagnosis of non-small cell lung cancer who underwent anatomical pulmonary resection after neoadjuvant treatment were retrospectively analyzed. Demographic, clinical, radiological, and pathological characteristics of the patients were recorded. The patients were classified as pathological complete response and nonpathological complete response according to the presence of tumors in the pathology reports. Predictive factors for pathological complete response and its prognostic significance were analyzed. The mean follow-up was 35±20 (range, 0 to 110) months. Of the patients, 30 (27%) achieved a pathological complete response. Reduction rate in tumor size was significantly higher in the responsive group (32.5±21.6% vs. 19.2±18.8%, respectively) and was a predictor of pathological complete response independent from the T and N factors (p=0.004). Survival of the responsive patients was significantly longer than unresponsive patients (75±9 vs. 30±4 months, respectively; p<0.001). During follow-up, tumor recurrence was seen in 30 patients. Recurrence was observed in only one patient in the responsive group, while 29 patients in the unresponsive group had recurrence or metastasis. Tumor shrinkage rate after neoadjuvant treatment in non-small cell lung cancer is a predictive factor for pathological complete response. Survival of patients with a pathological complete response is also significantly longer than unresponsive patients.
Sections du résumé
BACKGROUND
BACKGROUND
This study aims to investigate the factors associated with pathological complete response following neoadjuvant treatment and to examine the prognostic value of pathological complete response in patients with non-small cell lung cancer undergoing surgical resection.
METHODS
METHODS
Between February 2009 and January 2016, a total of 112 patients (96 males, 16 females; mean age 60±8 years; range, 37 to 85 years) with the diagnosis of non-small cell lung cancer who underwent anatomical pulmonary resection after neoadjuvant treatment were retrospectively analyzed. Demographic, clinical, radiological, and pathological characteristics of the patients were recorded. The patients were classified as pathological complete response and nonpathological complete response according to the presence of tumors in the pathology reports. Predictive factors for pathological complete response and its prognostic significance were analyzed.
RESULTS
RESULTS
The mean follow-up was 35±20 (range, 0 to 110) months. Of the patients, 30 (27%) achieved a pathological complete response. Reduction rate in tumor size was significantly higher in the responsive group (32.5±21.6% vs. 19.2±18.8%, respectively) and was a predictor of pathological complete response independent from the T and N factors (p=0.004). Survival of the responsive patients was significantly longer than unresponsive patients (75±9 vs. 30±4 months, respectively; p<0.001). During follow-up, tumor recurrence was seen in 30 patients. Recurrence was observed in only one patient in the responsive group, while 29 patients in the unresponsive group had recurrence or metastasis.
CONCLUSION
CONCLUSIONS
Tumor shrinkage rate after neoadjuvant treatment in non-small cell lung cancer is a predictive factor for pathological complete response. Survival of patients with a pathological complete response is also significantly longer than unresponsive patients.
Identifiants
pubmed: 32175158
doi: 10.5606/tgkdc.dergisi.2020.18240
pmc: PMC7067008
doi:
Types de publication
Journal Article
Langues
eng
Pagination
166-174Informations de copyright
Copyright © 2020, Turkish Society of Cardiovascular Surgery.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Références
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
Lung Cancer. 1998 Jul;21(1):1-6
pubmed: 9792048
Lancet. 2009 Aug 1;374(9687):379-86
pubmed: 19632716
Ann Thorac Surg. 2012 Jun;93(6):1807-12
pubmed: 22632486
Lung Cancer. 2016 Jun;96:56-62
pubmed: 27133751
J Thorac Oncol. 2018 Dec;13(12):1818-1831
pubmed: 30268698
J Clin Oncol. 2008 Feb 1;26(4):644-9
pubmed: 18235125
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):456-63
pubmed: 22543206
J Clin Oncol. 2002 Jan 1;20(1):247-53
pubmed: 11773176
Ann Thorac Surg. 2016 Jan;101(1):211-7
pubmed: 26279367
J Clin Oncol. 2007 Jan 20;25(3):313-8
pubmed: 17235046
Cancer Manag Res. 2019 Jan 21;11:943-953
pubmed: 30718965
Gan To Kagaku Ryoho. 2009 Dec;36(13):2495-501
pubmed: 20009446
Eur J Cardiothorac Surg. 2006 Nov;30(5):787-92
pubmed: 16971134
Cancer. 2012 Dec 15;118(24):6126-35
pubmed: 22674529
Clin Lung Cancer. 2013 Jul;14(4):418-24
pubmed: 23291258
Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206
pubmed: 15464470
Eur J Cardiothorac Surg. 2011 Jun;39(6):1022-7
pubmed: 21112217
Eur J Cardiothorac Surg. 2019 Sep 1;56(3):604-611
pubmed: 30809654
Ann Thorac Surg. 2004 Dec;78(6):1903-9; discussion 1909
pubmed: 15560998
Chest. 1995 Jun;107(6 Suppl):294S-297S
pubmed: 7781409
J Thorac Oncol. 2013 Jul;8(7):860-5
pubmed: 23478543
J Thorac Oncol. 2019 Mar;14(3):482-493
pubmed: 30503889
Radiother Oncol. 2016 Jun;119(3):480-6
pubmed: 27085484
Br J Cancer. 2006 Apr 24;94(8):1099-106
pubmed: 16622435
J Clin Oncol. 1993 Sep;11(9):1757-62
pubmed: 8394881
Front Oncol. 2018 Jan 23;8:5
pubmed: 29410947
J Thorac Oncol. 2012 May;7(5):841-9
pubmed: 22722786